FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 53 filers reported holding FATE THERAPEUTICS INC in Q1 2017. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $27,823,785 | -55.5% | 13,124,427 | 0.0% | 1.32% | -44.8% |
Q2 2023 | $62,472,273 | -15.4% | 13,124,427 | +1.3% | 2.40% | -25.2% |
Q1 2023 | $73,856,165 | -43.5% | 12,957,222 | 0.0% | 3.20% | -40.1% |
Q4 2022 | $130,738,370 | -55.0% | 12,957,222 | 0.0% | 5.35% | -52.5% |
Q3 2022 | $290,371,000 | -9.6% | 12,957,222 | 0.0% | 11.26% | -8.1% |
Q2 2022 | $321,080,000 | -36.1% | 12,957,222 | 0.0% | 12.26% | -21.8% |
Q1 2022 | $502,351,000 | -33.7% | 12,957,222 | 0.0% | 15.68% | -9.0% |
Q4 2021 | $758,127,000 | -1.3% | 12,957,222 | 0.0% | 17.24% | +28.7% |
Q3 2021 | $767,975,000 | -31.7% | 12,957,222 | 0.0% | 13.39% | -19.5% |
Q2 2021 | $1,124,557,000 | +5.3% | 12,957,222 | 0.0% | 16.64% | +10.6% |
Q1 2021 | $1,068,323,000 | -7.0% | 12,957,222 | +2.6% | 15.05% | +8.2% |
Q4 2020 | $1,148,422,000 | +127.5% | 12,629,737 | 0.0% | 13.91% | +50.0% |
Q3 2020 | $504,811,000 | +16.5% | 12,629,737 | 0.0% | 9.27% | +15.8% |
Q2 2020 | $433,326,000 | +73.9% | 12,629,737 | +12.6% | 8.00% | +14.5% |
Q1 2020 | $249,125,000 | +13.5% | 11,216,809 | 0.0% | 6.98% | +33.0% |
Q4 2019 | $219,513,000 | +26.0% | 11,216,809 | 0.0% | 5.25% | -9.9% |
Q3 2019 | $174,197,000 | -17.2% | 11,216,809 | +8.3% | 5.83% | -2.1% |
Q2 2019 | $210,301,000 | +15.5% | 10,359,666 | 0.0% | 5.95% | +11.7% |
Q1 2019 | $182,019,000 | +36.9% | 10,359,666 | 0.0% | 5.33% | -0.4% |
Q4 2018 | $132,915,000 | -21.2% | 10,359,666 | 0.0% | 5.34% | +2.9% |
Q3 2018 | $168,759,000 | +123.6% | 10,359,666 | +55.6% | 5.19% | +102.5% |
Q2 2018 | $75,479,000 | +16.2% | 6,655,962 | 0.0% | 2.56% | +2.2% |
Q1 2018 | $64,962,000 | +94.5% | 6,655,962 | +21.8% | 2.51% | +72.8% |
Q4 2017 | $33,394,000 | +494.3% | 5,465,486 | +285.1% | 1.45% | +424.2% |
Q3 2017 | $5,619,000 | +22.2% | 1,419,058 | 0.0% | 0.28% | -1.1% |
Q2 2017 | $4,598,000 | -28.8% | 1,419,058 | 0.0% | 0.28% | -33.2% |
Q1 2017 | $6,457,000 | +81.3% | 1,419,058 | 0.0% | 0.42% | +36.5% |
Q4 2016 | $3,562,000 | -19.9% | 1,419,058 | -0.4% | 0.31% | -13.3% |
Q3 2016 | $4,446,000 | +74.1% | 1,425,158 | -5.1% | 0.35% | +45.1% |
Q2 2016 | $2,554,000 | -4.6% | 1,502,180 | +1.0% | 0.24% | -10.9% |
Q1 2016 | $2,677,000 | -66.5% | 1,486,980 | -37.3% | 0.27% | -54.2% |
Q4 2015 | $7,990,000 | -27.8% | 2,371,001 | +14.3% | 0.60% | -28.6% |
Q3 2015 | $11,059,000 | -14.9% | 2,074,836 | +3.4% | 0.84% | -21.2% |
Q2 2015 | $12,988,000 | – | 2,007,446 | – | 1.06% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
JOHNSON & JOHNSON | 3,379,064 | $131,006,000 | 24.77% |
Redmile Group, LLC | 12,957,222 | $502,351,000 | 15.68% |
Grosvenor Holdings, L.L.C. | 1,037,256 | $40,214,000 | 7.85% |
Casdin Capital, LLC | 3,400,000 | $131,818,000 | 5.91% |
Ally Bridge Group (NY) LLC | 181,500 | $7,037,000 | 5.22% |
DAFNA Capital Management LLC | 500,930 | $19,421,000 | 5.06% |
Deep Track Capital, LP | 2,000,000 | $77,540,000 | 4.97% |
Artal Group S.A. | 2,000,000 | $77,540,000 | 3.25% |
Tri Locum Partners LP | 190,345 | $7,380,000 | 2.88% |
ARK Investment Management | 10,988,182 | $426,012,000 | 1.78% |